港股異動 | 和黃醫藥(0013.HK)大漲12.58% 上半年總收入增長47%至1.574億美元
格隆匯7月29日丨和黃醫藥(0013.HK)大漲12.58%,報74.3港元,總市值642億港元。和黃醫藥昨晚公佈中期業績,2021年上半年,總收入增長47%至1.574億美元;腫瘤/免疫業務綜合收入增長161%至4,290萬美元。公司的中國腫瘤商業團隊規模已擴大至約540名員工。此外,公司與阿斯利康已啟動一項沃瑞沙®的II期臨牀試驗。沃瑞沙®是一種強效、高選擇性的口服小分子間質上皮轉化因子(MET)抑制劑,用於治療MET擴增的晚期或轉移性胃癌或胃食管結合部腺癌患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.